The Feasibility and Effects of Acupuncture on Quality of Life Scores During Chemotherapy in Ovarian Cancer: Results from a Pilot, Randomized Sham-Controlled Trial.
Within a pilot trial regarding chemotherapy-induced neutropenia, the secondary aim of the main study was explored. This involved measuring the effects-as shown on two key measurement scales reflecting quality of life (QoL)-of verum versus sham acupuncture on patients with ovarian cancer during chemotherapy.



The aim of this substudy was to determine the feasibility of determining the effects of verum acupuncture versus sham acupuncture on QoL in patients with ovarian cancer during chemotherapy.



This was a randomized, sham-controlled trial.



The trial was conducted at two cancer centers.



Patients with ovarian cancer (N=21) who were receiving chemotherapy-primarily intravenous carboplatin and paclitaxel-participated in this substudy.



The participants were given either active or sham acupuncture 1 week prior to cycle 2 of chemotherapy. There were ten sessions of acupuncture, with manual and electro-stimulation over a 4-week period.



The European Organization for Research and Treatment of Cancer-Quality-of-Life Questionnaire-Core 30 Item (EORTC-QLQ-C30) and the Quality of Life Questionnaire-Ovarian Cancer Module-28 Item (QLQ-OV28) were administered to the patients at baseline and at the end of their acupuncture sessions.



Of the original 21, 15 patients (71%) completed the study, and 93% of them completed the questionnaires. The EORTC-QLQ-C30 subscores were improved in the acupuncture arm, including the mean scores of social function (SF), pain, and insomnia (p=0.05). However, after adjusting for baseline differences, only the SF score was significantly higher in the active acupuncture arm, compared with the sham acupuncture arm (p=0.03).



It appears feasible to conduct a randomized sham-controlled acupuncture trial measuring QoL for patients with ovarian cancer who are undergoing chemotherapy. Acupuncture may have a role in improving QoL during chemotherapy.
Leonard P. Zakim Center for Integrative Therapies, Dana-Farber Cancer Institute , Boston, MA. ; The New England School of Acupuncture , Newton, MA.
Weidong
W
Lu
Department of Medical Oncology, Dana-Farber Cancer Institute , Boston, MA.
Ursula A
UA
Matulonis
The New England School of Acupuncture , Newton, MA.
Julie E
JE
Dunn
Biostatistics Center, Massachusetts General Hospital , Boston, MA.
Hang
H
Lee
Leonard P. Zakim Center for Integrative Therapies, Dana-Farber Cancer Institute , Boston, MA.
Anne
A
Doherty-Gilman
Leonard P. Zakim Center for Integrative Therapies, Dana-Farber Cancer Institute , Boston, MA.
Elizabeth
E
Dean-Clower
Department of Gynecologic Oncology & Medicine, Massachusetts General Hospital , Boston, MA.
Annekathryn
A
Goodman
Osher Center for Integrative Medicine, Harvard Medical School and Brigham and Women's Hospital , Boston, MA.
Roger B
RB
Davis
Osher Center for Integrative Medicine, Harvard Medical School and Brigham and Women's Hospital , Boston, MA.
Julie
J
Buring
Osher Center for Integrative Medicine, Harvard Medical School and Brigham and Women's Hospital , Boston, MA.
Peter
P
Wayne
Leonard P. Zakim Center for Integrative Therapies, Dana-Farber Cancer Institute , Boston, MA.
David S
DS
Rosenthal
Department of Gynecologic Oncology & Medicine, Massachusetts General Hospital , Boston, MA.
Richard T
RT
Penson
Acupuncture; Chemotherapy; EORTC; Neutropenia; Ovarian Cancer; Quality of Life; Randomized Controlled Trial